OCP/DARS new clinical studies IDIQ 5 year contract with $50 M ceiling
Past New Requirement Updated
- Agency
-
Food and Drug Administration
Department of Health and Human Services
- Solicitation expected
- Estimated value
- $50,000,000 to $100,000,000
- Set-aside
- No set-aside
Forecast facts
- Anticipated award
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Points of contact
-
- Christopher Scott christopher.scott@fda.hhs.gov
- tbd@fda.gov
Forecast details come from HHS's procurement forecast. Agencies' dates and values are estimates.
About this forecast
The Food and Drug Administration (FDA) is forecasting a new Indefinite Delivery/Indefinite Quantity (IDIQ) contract for clinical studies in the biotechnology research and development sector. The contract is estimated to be released for solicitation on November 1, 2025, with an anticipated award date of January 1, 2026. The primary objective is to support new clinical studies over a five-year contract period.
The contract has a $50 million ceiling and falls under NAICS code 541714 for Research and Development in Biotechnology. The primary point of contact is Christopher Scott, who can be reached at christopher.scott@fda.hhs.gov within the Food and Drug Administration. While specific performance location details are not provided, interested contractors should note this is a non-set-aside procurement opportunity in the biotechnology research domain.
Forecast text
OCP/DARS new clinical studies IDIQ 5 year contract to support new clinical studies 5 year IDIQ w/50mil ceiling.
On GovTribe
Work this forecast
- Track it in your pipeline
- Find teaming partners
- Similar forecasts
- Ask GovTribe AI about this forecast